Pulmonary Function Testing Systems Market Size & Share 2026-2035

Pulmonary Function Testing Systems Market Size

The global pulmonary function testing systems market was valued at USD 3.1 billion in 2025. The market is expected to grow from USD 3.2 billion in 2026 to USD 5.9 billion in 2035, growing at a CAGR of 6.9% during the forecast period, according to the latest report published by Global Market Insights Inc.

Pulmonary function testing systems are a set of medical devices and equipment used to evaluate the respiratory function of an individual. These systems measure various aspects of lung function, including the volume of air a person can inhale and exhale, the speed of the breath, and the efficiency of the lungs in exchanging gases.
 

The key players in the pulmonary function testing systems market are Baxter, COSMED, ndd Medical Technologies, PHILIPS, and VYAIRE MEDICAL. These players compete in the market through continuous product innovation, strategic mergers and acquisitions, geographic expansion, and investments in advanced technologies, while also focusing on clinical collaborations and regulatory approvals to strengthen their global market presence.
 

The market increased from USD 2.6 billion in 2022 to USD 2.9 billion in 2024, with a historic growth rate of 5.1%. The market has shown steady expansion in recent years, supported by the rising prevalence of chronic respiratory diseases and growing innovations in pulmonary function testing systems.
 

Moreover, the rising prevalence of respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer, drives the adoption of pulmonary function testing systems. For instance, according to the World Health Organization (WHO), COPD affected 391 million people globally in 2022, while asthma impacted 339 million individuals. Similarly, the Centers for Disease Control and Prevention (CDC) reported that lung cancer cases in the U.S. increased by 2.3% annually between 2021 and 2023. These testing systems are essential for early diagnosis and continuous monitoring of respiratory conditions, enabling effective disease management.
 

Furthermore, innovations in pulmonary function testing systems, including portable devices, advanced spirometers, and integrated software for precise analysis, are driving market growth. These advancements improve diagnostic accuracy, ease of use, and patient comfort, encouraging wider adoption.

Pulmonary Function Testing Systems Market Trends

The pulmonary function testing systems industry is witnessing significant growth driven by surging demand for integrated advanced technologies, rising use in occupational health and industrial applications, and increasing focus on digital health solutions, among other factors, which are boosting the industry growth.
 

• Further, there is a growing demand for portable pulmonary function testing devices suitable for home use. These devices allow patients to monitor their respiratory health conveniently and continuously, meeting the needs of individuals with chronic respiratory conditions and supporting telehealth solutions.
   
• Additionally, the market is witnessing the adoption of advanced technologies such as artificial intelligence in healthcare, machine learning, and the Internet of Things (IoT) in healthcare. These innovations enhance diagnostic precision, automate data analysis, and provide real-time monitoring, ultimately improving the efficiency of pulmonary function testing systems and contributing to the increasing market demand.
   

Pulmonary Function Testing Systems Market Analysis

• Handheld pulmonary function testing systems are compact, easy to use, and ideal for point-of-care settings and home monitoring. Their portability allows healthcare providers and patients to perform tests in various environments, which enhances their adoption.
   
• Moreover, these devices are more affordable than full-scale laboratory-based pulmonary function testing systems. This cost advantage makes them accessible to small clinics, primary care centers, and patients in resource-limited settings. This is anticipated to boost the segmental growth in the market.
   
• The tabletop segment was valued at USD 1.2 billion in 2025 and is expected to reach USD 2.2 billion by 2035, driven by its widespread use in hospitals and diagnostic laboratories for comprehensive pulmonary assessments. The increasing prevalence of chronic respiratory diseases and the growing demand for accurate, high-capacity testing systems are further supporting segment growth.
   

Based on test type, the pulmonary function testing systems market is segmented into spirometry, exercise stress test, lung volume test, high altitude simulation testing, gas diffusion test, and other test types. The spirometry segment accounted for USD 1.4 billion in market revenue in 2025 and is anticipated to grow at a CAGR of 7.2% between 2026 and 2035.
 

• Spirometry is a fundamental test for diagnosing and monitoring respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. By measuring airflow and assessing lung function, it helps identify issues like airway obstruction, driving demand for spirometry systems in both clinical and home settings.
   
• Additionally, modern spirometry devices have become more accurate, user-friendly, and portable. Advances such as digital spirometers with touch-screen interfaces, wireless capabilities, and integration with health data platforms have made spirometry more appealing to both healthcare providers and patients, further fueling market growth.
   
• The exercise stress test segment was valued at USD 576.1 million in 2025 and is expected to reach USD 1.2 billion by 2035, growing at a CAGR of 7.8% during the forecast period. The segment is gaining traction due to the increasing need to evaluate pulmonary and cardiovascular function under physical exertion, particularly in patients with chronic respiratory and cardiac conditions. Additionally, rising awareness of early disease diagnosis and growing adoption of advanced cardiopulmonary exercise testing systems in specialty clinics and hospitals are supporting steady segment expansion.
   
• The lung volume test segment was valued at USD 406.4 million in 2025 and is expected to reach USD 696.3 million by 2035, driven by the increasing prevalence of chronic obstructive pulmonary disease (COPD), asthma, and other restrictive lung disorders. Growing demand for accurate assessment of total lung capacity and residual volume in hospital and diagnostic settings is further contributing to steady segment growth.
   
• The high altitude simulation testing segment was valued at USD 285.2 million in 2025 and is expected to reach USD 535.6 million by 2035, driven by increasing demand for pre-flight fitness assessments and evaluation of patients with respiratory or cardiac conditions before air travel. Growing applications in aerospace medicine, defense sectors, and specialized pulmonary clinics are further supporting segment growth over the forecast period.
   
• The gas diffusion test segment was valued at USD 223.4 million in 2025 and is expected to reach USD 366.4 million by 2035, driven by the rising need to assess gas exchange efficiency in patients with interstitial lung diseases, pulmonary fibrosis, and emphysema. Increasing emphasis on early diagnosis and routine monitoring of chronic respiratory disorders in hospitals and specialty clinics is further supporting steady segment growth.
   
• The other test types segment is expected to witness steady growth over the forecast period, driven by the increasing adoption of specialized pulmonary assessments such as bronchial provocation and respiratory muscle strength testing. Expanding clinical applications, rising research activities, and growing awareness of comprehensive lung function evaluation are further contributing to gradual segment expansion.
   

Based on application, the pulmonary function testing systems market is segmented into chronic obstructive pulmonary disease, asthma, chronic shortness of breath, pulmonary fibrosis, and other applications. The chronic obstructive pulmonary disease segment dominated the market in 2025 with a market share of 40.1%.
 

• COPD is one of the leading causes of morbidity and mortality globally, particularly in older adults and smokers. The growing number of COPD cases due to lifestyle factors (e.g., smoking and pollution) and an aging population is driving the demand for pulmonary function testing systems to monitor and manage the disease effectively.
   
• Further, there is a rising global emphasis on managing chronic diseases like COPD. Regular monitoring of lung function helps track the progression of COPD and adjust treatment plans accordingly. This is encouraging healthcare providers to adopt pulmonary function testing systems for consistent patient management. This is anticipated to boost the segmental growth in the market.
   
• The asthma segment was valued at USD 791.7 million in 2025 and is expected to reach USD 1.4 billion by 2035, growing at a CAGR of 6.1% during the forecast period. The segment’s growth is primarily driven by the rising global prevalence of asthma across both pediatric and adult populations, coupled with increasing emphasis on early diagnosis and routine lung function monitoring. Additionally, growing awareness regarding disease management, expanding access to pulmonary function testing in outpatient settings, and advancements in portable spirometry devices are further supporting steady segment expansion.
   
• The chronic shortness of breath segment was valued at USD 428.5 million in 2025 and is expected to reach USD 739.2 million by 2035, driven by the increasing incidence of underlying respiratory and cardiovascular disorders such as COPD, interstitial lung disease, and heart failure. Growing emphasis on accurate differential diagnosis and continuous monitoring of pulmonary function in hospitals and specialty clinics is further contributing to the steady growth of this segment.
   
• The pulmonary fibrosis segment was valued at USD 374.9 million in 2025 and is expected to reach USD 796.4 million by 2035, driven by the rising prevalence of interstitial lung diseases and increasing need for early detection and disease progression monitoring. Advancements in diffusion capacity testing and growing clinical focus on comprehensive pulmonary assessment are further supporting the expansion of this segment over the forecast period.
   
• The other applications segment is expected to witness steady growth over the forecast period, driven by expanding use of pulmonary function testing in pre-operative evaluations, occupational health assessments, and clinical research studies. Increasing awareness of preventive respiratory care and growing adoption of routine lung screening programs are further contributing to the gradual expansion of this segment.

Based on end use, the pulmonary function testing systems market is segmented into hospitals & clinics, diagnostic centers, homecare settings, and other end users. The hospitals & clinics segment dominated the market in 2025 and is anticipated to reach USD 2.6 billion by the end of the forecast period.
 

• Hospitals and clinics are placing greater emphasis on preventive care and the early detection of respiratory conditions. Regular pulmonary function testing, such as spirometry, helps identify lung function abnormalities in their early stages, enabling timely intervention and improving patient outcomes.
   
• Furthermore, the adoption of advanced, user-friendly, and more accurate PFT systems in hospitals and clinics is on the rise. New devices with features like digital interfaces, wireless connectivity, and integration with electronic health records (EHR) are streamlining testing procedures, enhancing diagnostic accuracy, and improving patient care.
   
• The diagnostic centers segment was valued at USD 873.8 million in 2025 and is expected to reach USD 1.6 billion by 2035, growing at a CAGR of 6.3% during the forecast period. This growth is attributed to the increasing demand for specialized pulmonary testing services, rising referrals for early respiratory disease diagnosis, and expanding availability of advanced spirometry and diffusion testing systems. Additionally, the growing preference for outpatient diagnostic procedures and improved accessibility to standalone testing facilities are further supporting segment expansion.
   
• The homecare settings segment was valued at USD 575.4 million in 2025 and is expected to reach USD 1.2 billion by 2035, driven by the increasing shift toward remote patient monitoring and home-based management of chronic respiratory diseases. Growing adoption of portable and handheld pulmonary function testing devices, along with rising preference for convenient and cost-effective care solutions, is further supporting strong segment growth.
   
• The other end users segment is expected to witness steady growth over the forecast period, driven by increasing utilization of pulmonary function testing systems in research institutions, academic centers, and occupational health settings. Expanding clinical trials, rising awareness of preventive respiratory screening, and growing demand for specialized lung function assessment are further contributing to gradual segment expansion.

North America Pulmonary Function Testing Systems Market

North America dominated the global pulmonary function testing systems industry, accounting for a market share of 47.6% in 2025.
 

• The U.S. market reached USD 1.4 billion in 2025 and is anticipated to grow at a CAGR of 5.8% from 2026 to 2035.
   
• The U.S. is at the forefront of innovation in medical technologies. Advanced pulmonary function testing systems, such as digital spirometers and portable devices with wireless connectivity, are widely adopted across the country. These innovations make testing more accurate, efficient, and patient-friendly, thus increasing demand for these systems.
   
• Additionally, healthcare expenditure in the U.S. continues to increase, with diagnostic equipment remaining a key investment area. According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending grew by 2.7% in 2021, reaching USD 4.3 trillion, followed by a 4.1% increase in 2022 to USD 4.5 trillion. Healthcare facilities, including hospitals, clinics, and outpatient care centers, are investing in pulmonary function testing systems to enhance respiratory care services and improve patient outcomes, thereby increasing the availability of these devices.
   

Europe Pulmonary Function Testing Systems Market

The Europe pulmonary function testing systems industry accounted for USD 687.9 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• infrastructure, strong diagnostic capabilities, and widespread availability of advanced spirometry and lung diffusion testing systems across hospitals and diagnostic centers.
   
• Additionally, favorable reimbursement policies, increasing geriatric population, and rising focus on early disease detection are supporting sustained market demand. Government initiatives aimed at improving respiratory health management and the strong presence of leading medical device manufacturers further reinforce the region’s market position.
   

Asia Pacific Pulmonary Function Testing Systems Market

The Asia Pacific pulmonary function testing systems industry is anticipated to grow at the highest CAGR of 8.8% during the forecast period.
 

• Asia Pacific held a considerable market share and is anticipated to witness the fastest growth during the forecast period. Rapid urbanization, increasing air pollution levels, rising smoking rates, and growing incidence of respiratory disorders are key factors contributing to the rising demand for pulmonary diagnostic systems. Expanding healthcare infrastructure in countries such as China, India, and Southeast Asian nations is further supporting adoption.
   
• Moreover, increasing healthcare expenditure, improving access to diagnostic services, and growing awareness regarding preventive respiratory care are accelerating market expansion. The rising adoption of portable and handheld pulmonary function testing devices in both urban and semi-urban areas is also driving regional growth.
   

Latin America Pulmonary Function Testing Systems Market

The Latin America pulmonary function testing systems industry accounted for USD 177.5 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Latin America accounted for a moderate share of the market, supported by improving healthcare infrastructure and growing awareness about early diagnosis of respiratory diseases. Countries such as Brazil and Mexico are witnessing increased investments in hospital and diagnostic center upgrades, which are fostering demand for advanced pulmonary function testing equipment.
   
• In addition, the rising prevalence of asthma and chronic respiratory conditions, coupled with the gradual adoption of portable diagnostic solutions, is contributing to steady market growth. Expanding private healthcare sector participation and government initiatives aimed at strengthening diagnostic capabilities are expected to further enhance regional market performance.
   

Middle East and Africa Pulmonary Function Testing Systems Market

The Middle East and Africa pulmonary function testing systems industry accounted for USD 98.6 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• The Middle East & Africa region accounted for a smaller yet steadily growing share of the pulmonary function testing systems industry. The increasing prevalence of respiratory diseases, particularly in urban populations exposed to high pollution levels, is driving demand for advanced lung function testing systems.
   
• Furthermore, ongoing healthcare infrastructure development, especially in GCC countries, and rising government investments in diagnostic and specialty care services are supporting market growth. Gradual adoption of modern medical technologies and improving access to respiratory care services across select African nations are expected to contribute to sustained expansion over the forecast period.
   

Pulmonary Function Testing Systems Market Share

The pulmonary function testing systems industry is marked by the presence of leading global players like Baxter, COSMED, ndd Medical Technologies, PHILIPS, and VYAIRE MEDICAL, among others, which collectively held approximately 29% of the total market share in 2025. These companies focus on technological advancements such as portable and handheld spirometers, along with innovations in software for data integration and analysis.
 

Additionally, players are increasingly expanding their product portfolios to offer solutions for remote monitoring and home-based testing, driven by the rise in chronic respiratory conditions and the growing demand for non-invasive diagnostic tools. Partnerships and collaborations with hospitals and clinics are common strategies to strengthen market presence.
 

Pulmonary Function Testing Systems Market Companies

A few of the prominent players operating in the pulmonary function testing systems industry include:

• Baxter
• CHEST M.I
• COSMED
• ECO MEDICS
• FUKUDA SANGYO
• GANSHORN SCHILLER GROUP
• Geratherm Respiratory
• medical equipment Europe
• MGC DIAGNOSTICS
• MINATO MEDICAL SCIENCE
• MORGAN
• ndd Medical Technologies
• PHILIPS
• Vitalograph
• Vyaire MEDICAL
   

• Baxter

Baxter’s portfolio of connected medical devices, infusion technologies, monitoring solutions, and digital tools positions the company as a key enabler of integrated respiratory‑care pathways that complement diagnostic workflows such as PFT. Their strategic emphasis on integrated care delivery and interoperability supports hospitals seeking unified monitoring and diagnostic data streams.
 

• PHILIPS

Philips has long been a leading brand in sleep and respiratory care, giving it an inherent competitive advantage in clinical environments that also rely on PFT systems. Their market influence across respiratory therapists, pulmonology clinics, and home‑care providers positions Philips as a trusted ecosystem partner for pulmonary diagnostics integration.
 

Pulmonary Function Testing Systems Industry News:

• In September 2024, Vitalograph announced the acquisition of Morgan Scientific, a respiratory diagnostics company. This acquisition may help the company in strengthening its U.S. commercial footprint and enabling it to meet the growing global demand for its innovative solutions, particularly in advanced pulmonary function testing solutions.
   
• In April 2021, Vyaire Medical announced the European launch of ArtiQ.PFT is an automated tool driven by artificial intelligence that instantly interprets pulmonary function tests (PFTs). This product launch positioned the company as a leader in innovative healthcare solutions, driving growth and reinforcing its commitment to advancing respiratory care.
   

The pulmonary function testing systems market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Handheld
• Tabletop

Market, By Test Type

• Spirometry
• Exercise stress test
• Lung volume test
• High altitude simulation testing
• Gas diffusion test
• Other test types

Market, By Application

• Chronic obstructive pulmonary disease
• Asthma
• Chronic shortness of breath
• Pulmonary fibrosis
• Other applications

Market, By End Use

• Hospitals & clinics
• Diagnostic centers
• Homecare settings
• Other end users
   

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE